{"id":521664,"date":"2021-08-02T16:38:06","date_gmt":"2021-08-02T20:38:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"modified":"2021-08-02T16:38:06","modified_gmt":"2021-08-02T20:38:06","slug":"paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","title":{"rendered":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Aug.  02, 2021  (GLOBE NEWSWIRE) &#8212; Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\u00a0military use, today announced that on July 30, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company&#8217;s board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.<\/p>\n<p>The stock options are to acquire, in the aggregate, 4,800 shares of the Company\u2019s common stock at a per share exercise price of $5.20, the closing sales price on July 30, 2021, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee\u2019s continuous service. The restricted stock units are to acquire, in the aggregate, 11,100 shares of the Company\u2019s common stock and shall vest upon the conclusion of a 36-month\u00a0vesting period, under which 100% of the restricted stock units will vest after 36 months of employment, subject to the employee\u2019s continuous service. The stock options and restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement and restricted stock unit award agreement covering each grant.<\/p>\n<p>\n        <strong>About Paratek Pharmaceuticals, Inc.<\/strong><br \/>\n        <br \/>Paratek Pharmaceuticals, Inc.\u00a0is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and\u00a0military use.<\/p>\n<p>The Company&#8217;s lead commercial product, NUZYRA\u00ae\u00a0(omadacycline), is\u00a0a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with\u00a0Zai\u00a0Lab for the development and commercialization of omadacycline in the greater\u00a0China\u00a0region and retains all remaining global rights.<\/p>\n<p>Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by\u00a0<em>Mycobacterium abscessus<\/em>\u00a0Complex (MABc) with NUZYRA. Paratek estimates this opportunity represents a potential $1.0 billion addressable market in the U.S.<\/p>\n<p>Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA\u00ae\u00a0(sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to\u00a0Almirall, LLC\u00a0(Almirall). Paratek retains the development and commercialization rights for sarecycline in the rest of the world.<\/p>\n<p>In 2019, Paratek was awarded a contract from BARDA, valued up to $284.5 million,\u00a0to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TYt2rixW0s_ZjwszvpIC6hqgnWFmxT6517vfLDB60JVh8QVnbyUym_5_DizNmHC-01HDRwBWZ8OFWeLIutwt1owiTHaoGD2XAzzFqewoVnBdvz5e41zAMPfIrLiQCfNF5cAhhSxHRaaIpQWx3XASwpLmFUkZWoAUoE3pbhwkHbFYLIre2x5LkT8lISAS860xJefQZM70pvjZ9ZWno8-fH8lNoxWdehQUj9GDJU90By6yxzDvQn8uwX0179NAB7RQl-i-uZiE6KrAYjv5U8XrrA==\" rel=\"nofollow noopener\" target=\"_blank\">www.ParatekPharma.com<\/a>\u00a0or follow @ParatekPharma\u00a0on Twitter.<\/p>\n<p>\n        <strong>About NUZYRA\u00ae<\/strong><br \/>\n        <br \/>NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.<\/p>\n<p>Please see full Prescribing Information for NUZYRA at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xUjRnKCtQWwIdo1OBr2yjulaJUY_8SsHOpEj5rjknIdEBzGCpomXejSw9P2J58NyO4xDmFLQE1rZjrA9T-yS2pmnBpoRo-d8Z3kArTL30b4nqywAAbgjmwjgC723aELRDqcQkIRUDRNe0-puICo0mvCQgKodbU4MXF9I5A03MlJ8KOBcCAug8K8p24FiBJ6Ca6jJtrU6wtyujy39k7LF4CG7I6rGPYO-QsGEh1xFdzY=\" rel=\"nofollow noopener\" target=\"_blank\">www.NUZYRA.com<\/a>.<\/p>\n<p>\n        <strong>CONTACT<\/strong>:<br \/>For Investors:<br \/>Hans Vitzthum<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xWgIGyFEoMLWxkZlCmyetct7q4YfOB5TgvoTBUmNFbgZvCwPG-HXNCkQEAjoq2z7kkXUeeEYKsE0VklBEHS5VpVAZk6WJ8qVg-y2OW7hEAA=\" rel=\"nofollow noopener\" target=\"_blank\">ir@ParatekPharma.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9qfZA0vzQagTIRYj6EeMmH622JQmR4s9JM782pT-q5cdbQ6A98RpOTV2YNqGhyyYC5do5NJlaV_zTX-tOLGrPw==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>Phone: 617-430-7578<\/p>\n<p>For Media:<br \/>Beth Kramli <br \/>Scient PR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=092IOuu9tR5447-qyfTtfe93Zl1TBEQ--kEpddC69MHhmz2mxFSJQwSBdOVbrzYUr1OnWdQ5t84744y19H3zHg==\" rel=\"nofollow noopener\" target=\"_blank\">Beth@scientpr.com<\/a><br \/>Phone: 908-568-9721<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/71d9acb7-e023-4cd7-a509-3d8199383c28\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\u00a0military use, today announced that on July 30, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company&#8217;s board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-521664","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\u00a0military use, today announced that on July 30, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company&#8217;s board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material &hellip; Continue reading &quot;Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-02T20:38:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-08-02T20:38:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"},\"wordCount\":609,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\",\"name\":\"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\",\"datePublished\":\"2021-08-02T20:38:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_locale":"en_US","og_type":"article","og_title":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) &#8212; Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and\u00a0military use, today announced that on July 30, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company&#8217;s board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material &hellip; Continue reading \"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-02T20:38:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)","datePublished":"2021-08-02T20:38:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"},"wordCount":609,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/","name":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=","datePublished":"2021-08-02T20:38:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMDk1NSM0MzM2MjQ3IzIwMjg2ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/paratek-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=521664"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/521664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=521664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=521664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=521664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}